beta-adrenergic modulation of human type-1/type-2 cytokine balance

Citation
Sk. Agarwal et Gd. Marshall, beta-adrenergic modulation of human type-1/type-2 cytokine balance, J ALLERG CL, 105(1), 2000, pp. 91-98
Citations number
31
Categorie Soggetti
Clinical Immunolgy & Infectious Disease",Immunology
Journal title
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
ISSN journal
00916749 → ACNP
Volume
105
Issue
1
Year of publication
2000
Part
1
Pages
91 - 98
Database
ISI
SICI code
0091-6749(200001)105:1<91:BMOHTC>2.0.ZU;2-S
Abstract
Background: Neuroendocrine mediators are increasingly recognized as immunom odulatory agents. Lymphocytes and monocytes express receptors for a variety of neuroendocrine mediators, including catecholamines, It has been reporte d that beta-adrenergic agonists decrease IFN-gamma production, with varying effects on IL-4 and 1L-5 production. Objective: Our purpose was to determine the effects of catecholamines (incl uding beta-adrenergic agonists) on the type-1/type-2 cytokine balance in te tanus-stimulated human PBMCs. Method: Human PBMCs were stimulated with tetanus in the presence of epineph rine (EPI), norepinephrine, or terbutaline, IFN-gamma, IL-4, IL-5, and IL-1 0 levels in the supernatants were determined by ELISA. Results: PBMCs stimulated in the presence of EPI produced decreased levels of IFN-gamma and increased levels of IL-10, IL-4, and 1L-5. A small decreas e in IFN-gamma production and an increase in IL-10, IL-4, and IL-5 producti on were also observed with norepinephrine. Terbutaline induced similar alte rations in the type-1/type-2 cytokine balance compared with EPI, indicating that the beta(2)adrenergic receptor is involved in these cytokine alterati ons. Furthermore, these cytokine alterations were blocked by propranolol. F inally, IL-12p70 prevented the cytokine alterations, suggesting that the me chanism of beta-adrenergic-induced cytokine alterations involves a decrease in IL-12. Conclusion: beta-Adrenergic agonists induce a shift in the human type-1/typ e-2 cytokine balance toward a type-2 response. These data provide a potenti al mechanism to explain the paradoxical increase in asthma morbidity and mo rtality associated with the chronic use of scheduled dosing of short-acting beta-adrenergic agonists.